Averna Therapeutics

Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA

Health Tech & Life Sciences
Active
Series A Ness Ziona, Israel Founded 2022
Total raised
$82.0M
Last: Series A 2024-06
Stage
Series A
Founded
2022
Headcount
51
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

Averna Therapeutics is a biotechnology company specializing in the development of genomic medicines aimed at treating a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's proprietary technology focuses on inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome. These regions are selected to allow stable gene integration without disrupting normal cellular functions. By encoding their medicines in RNA, Averna utilizes validated, non-viral delivery platforms that are designed to be safe, efficient, scalable, and cost-effective. This approach also permits redosing with the intent to achieve curative outcomes.

Funding history · 1 round · $82.0M total

2024-06
Series A $82.0M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2C

Tags

pharmaceuticalshealthcare